表紙
市場調査レポート

中国のモンテルカスト市場の分析

Investigation Report on China Montelukast Market, 2010-2019

発行 China Research and Intelligence 商品コード 296860
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
中国のモンテルカスト市場の分析 Investigation Report on China Montelukast Market, 2010-2019
出版日: 2015年05月28日 ページ情報: 英文 30 Pages
概要

中国国内には現在、ぜんそく患者が3000万人、アレルギー性鼻炎患者が3000〜4000万人存在しており、また環境汚染の悪化と共に患者数はさらに増加するものと思われます。モンテルカスト(montelukast)は最適な抗ぜんそく薬の一つとして考えられています。2005年の上市から2010年にかけて、同国のモンテルカスト市場は年平均(CAGR)45%もの速度で急成長してきました。競合企業が参入して以降は成長率は低下しましたが、それでも年間10%の成長率を維持しており、巨大な潜在的市場を抱えています。

当レポートでは、中国におけるモンテルカスト市場について分析し、中国国内での生産高および病院向け売上高・価格の動向(過去5年間分)、企業別・投薬形態別の市場シェア、主要メーカーのプロファイル、将来的な市場動向の見通し(今後5年間分)などを調査して、その結果をお届けします。

第1章 モンテルカストの関連概念

  • 定義
  • 症状
  • 世界市場での販売状況

第2章 中国のモンテルカスト市場の概要

  • 特許の現状
  • 主要メーカー
  • 市場規模

第3章 モンテルカストの売上高の分析

  • 売上高
  • 販売量

第4章 主要メーカーの市場シェアの分析

  • 市場シェア(金額ベース)
  • 市場シェア(数量ベース)

第5章 剤形別の市場規模の分析

  • 剤形別の市場シェア(金額ベース)
  • 剤形別の市場シェア(数量ベース)

第6章 モンテルカストの病院向け基準価格(企業別)

  • Sichuan Xicheng Otsuka Pharmaceutical Co., Ltd.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Merck & Co., Inc. (USA)
  • Merck Shark. Dohme, MSD(UK)

第7章 主要メーカーの分析

  • Sichuan Xicheng Otsuka Pharmaceutical Co., Ltd.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Merck & Co., Inc. (USA)

第8章 中国のモンテルカスト市場の将来展望

  • 市場規模の予測
  • 市場競争の予測

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 1505182

More than 300 million people in the world suffer from seasonal asthma to different degrees. The situation is more serious in seriously polluted countries and regions where tobacco consumption is high. Asthma and allergic rhinitis are common diseases in today's world whose incidence has kept increasing every year due to nowadays' severe air pollution.

Montelukast, developed by Merck, has been widely applied to the treatment of allergic rhinitis and asthma. Montelukast, a selective cysteinyl leukotriene receptor D4 antagonist, selectively combines with leukotriene in the airway and blocks the action of anaphylactic mediator so as to improve respiratory inflammation and keep airway open.

In 1998, Montelukast sodium tablets (10mg) and chewable tablets (5mg) first came into America's market on FDA's approval with a trade name of Singulair. In 2000 and 2002, Montelukast chewable tablets (4mg) and Montelukast granules (4mg) were approved to enter the market successively for the prevention and long-term treatment of asthma of adults and children aged at 2 or above 2.

After Singulair's US patent expired on Aug.3, 2012, FDA has approved the generic drug applications of over 10 drug makers, among which Teva introduced tablets, chewable tablets and oral granules while Dr. Reddy's introduced tablets and chewable tablets.

In 1999, Montelukast chewable tablets (5mg) and tablets(10mg) came into Chinese market on approval with a trade name of Singulair. Later, Montelukast chewable tablets (4mg) and granules(4mg) came into Chinese market on approval successively. The generic drugs of Montelukast tablets (10mg) and chewable tablets(5mg) made by Sichuan Otsuka was approved to enter the market in 2006 with a trade name of Bystine. Besides, there are also many other companies declaring generic drug in Chinese market.

According to CRI's survey on some sample hospitals in China, the annual sales CAGR of Montelukast in Chinese hospitals exceeded 45% during the period of 2005-2010. With the appearance of some competitive products, the increase of Montelukast in Chinese market has slowed since 2011, but still remaining an annual growth of over 10%. Its sales CAGR still reached 25.5% during the period of 2010-2014.

It has been shown that China has more than 30 million asthma patients and 300-400 million patients suffering from allergic rhinitis. As the environmental pollution worsens in China, the number of patients will keep going up. In China, Montelukast is regarded as one of the most effective antiasthmatic drugs and therefore is estimated to enjoy huge market potential.

Readers can get at least the following information from this report:

  • incidence of respiratory ailments in China
  • Montelukast's price in Chinese hospitals
  • the production status of generic drugs of Montelukast in China
  • major Montelukast manufacturers and their market share in China
  • Market outlook of Montelukast in China

The author suggests the following groups of people purchase this report:

  • manufacturers of Montelukast APIs and finished medicines
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese market of Montelukast or other medicines, please contact CRI for customized research service

Table of Contents

1. Relevant Conceptions of Montelukast

  • 1.1. Definition
  • 1.2. Indication
  • 1.3. Sales in Global Market

2. Market Profile of Montelukast in China

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Scale

3. Research of Montelukast Sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Regional Sales Value
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Regional Sales Volume

4. Research of Major Montelukast Manufacturers' Market Share in China

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Research of Dosage Forms of Montelukast in China

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Montelukast in Chinese Hospitals in 2014

  • 6.1. Sichuan Otsuka Pharmaceutical Co., Ltd.
  • 6.2. Lunan Pharmaceutical Co., Ltd.
  • 6.3. Merck. Co., Inc (USA)
  • 6.4. Merck Shark. Dohme, MSD(UK)

7. Major Manufacturers of Montelukast for Chinese Market in 2010-2014

  • 7.1. Sichuan Otsuka Pharmaceutical Co., Ltd.
  • 7.2. Lunan Pharmaceutical Co., Ltd.
  • 7.3. Merck Shark. Dohme, MSD

8. Market Outlook of Montelukast in China, 2015-2019

  • 8.1. Forecast of Market Scale
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Pharmaceutical Patent of Montelukast in China
  • Chart Sales Status of Montelukast in Chinese Market, 2010-2014
  • Chart Sales Value of Montelukast in China, 2010-2014 (unit in CNY million)
  • Chart Sales Value of Montelukast in Chinese Regions, 2010-2014 (unit in CNY million)
  • Chart Sales Volume of Montelukast in China, 2010-2014 (unit: million)
  • Chart Sales Volume of Montelukast in Chinese Regions, 2010-2014 (unit: million)
  • Chart Montelukast Manufacturers' Sales Value and Market Share in China, 2010-2014
  • Chart Sales Value and Market Share of Montelukast Made by Merck (UK) in China, 2010-2014
  • Chart Sales Value and Market Share of Montelukast Made by Sichuan Otsuka in China, 2010-2014
  • Chart Sales Value and Market Share of Montelukast Made by Lunan in China, 2010-2014
  • Chart Sales Value and Market Share of Montelukast Made by Merck (USA) in China, 2010-2014
  • Chart Market Share of Montelukast Manufacturers by Sales Volume, 2010-2014
  • Chart Montelukast Oral Granules' Sales Value and Market Share in China, 2010-2014
  • Chart Price of Montelukast Made by Sichuan Otsuka in Some Chinese Cities in 2014
  • Chart Price of Montelukast Made by Lunan in Some Chinese Cities in 2014
  • Chart Price of Montelukast Made by Merck (USA) in Some Chinese Cities in 2014
Back to Top